Company ProfilePremium

NeuroScientific Biopharmaceuticals Limited

Company Profile Analysis

Ticker: NSB.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
NeuroScientific Biopharmaceuticals Limited - Company showcase

Year Founded & Workforce

2002

1 Employees

NeuroScientific Biopharmaceuticals Limited logo

NeuroScientific Biopharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

NeuroScientific Biopharmaceuticals Limited Overview

NeuroScientific Biopharmaceuticals is a Perth-based, ASX-listed clinical-stage biotechnology company that, in June 2025, executed a decisive pivot from neuro-peptide drug discovery to allogeneic cell therapy. Through its acquisition of Isopogen WA Ltd, it now owns StemSmart™, a patented manufacturing process for bone-marrow-derived mesenchymal stromal/stem cells (MSCs) originally developed at Royal Perth Hospital, which it is positioning against treatment-refractory and fistulising Crohn's disease — an indication where the leading approved cell therapy in Europe (Takeda's Alofisel) has been withdrawn and biologic failure is common. Real-world data from a Therapeutic Goods Administration Special Access Scheme cohort (4 of 5 patients achieving a protocol-defined clinical response, no serious adverse events) and a historic 18-patient Phase 2 study underpin plans for two Phase 2 trials in Australia and the US, with initiation targeted by end-CY2026. Its legacy peptide EmtinB™ has been fully impaired and is being offered for out-licensing. The investment case is binary, capital-constrained and milestone-driven.


Company's own description. In its FY2026 Annual Report, the company describes its principal activity as research and development of biomedical products aimed at neurodegenerative conditions and immune-mediated inflammatory diseases. In its 2026 ASX releases, NSB characterises itself as a biotechnology company developing novel therapeutics for immune-mediated inflammatory disorders, centred on modulating pathological immune responses in chronic and degenerative conditions where existing therapies have limited efficacy or durability, with an aspiration toward first-in-class or best-in-class biologics (ASX announcement, 13 August 2026).

Independent characterisation. NSB is, in substance, a single-asset cell-therapy development company. Its economic value rests almost entirely on the StemSmart™ MSC platform, carried on balance sheet at A$10.27M (FY2026, Note 10) against total assets of A$15.18M. The company does not manufacture in-house; it has outsourced GMP production to Q-Gen Cell Therapeutics (a QIMR Berghofer-affiliated contract manufacturer in Brisbane) and clinical execution to Southern Star Research (an Australian CRO). Its operating model is therefore "virtual": a small executive team, an advisory board, and contracted service providers coordinated from a Perth office.

Business model. NSB's model is a classic development-and-partner biotech model. Management's own incentive design reveals the intended exit route: the CEO's 1.5 million performance rights vest only on execution of a definitive third-party development and/or commercialisation agreement for the MSC therapy with combined upfront and milestone value of at least US$150 million (FY2026 Annual Report, Remuneration Report). Analyst commentary on the June 2026 quarterly similarly noted the US IND-enabled Phase 2 is designed to attract global partners for Phase 3 development (Kalkine summary of the 28 July 2026 quarterly). NSB is therefore best understood as building a de-risked clinical data package for licensing or sale rather than a fully integrated commercial pharmaceutical company.

Revenue model.

Royalty obligations (outbound). East Metropolitan Health Service (EMHS) is entitled to a 4% royalty on future net sales derived from the MSC technology, and to acquire MSC cells from Isopogen at cost for public patients in the WA public health system (FY2026 Annual Report, Note 20; June 2025 Quarterly Activity Report). The University of Tasmania retains an equity-based milestone entitlement of A$250,000 on EmtinB (Milestone 3: IND or equivalent regulatory acceptance).

Value-chain position. NSB sits at the discovery-to-clinical-development stage. Upstream inputs (donor bone marrow, GMP manufacturing, cleanroom capacity) are contracted; downstream activities (Phase 3, regulatory approval, commercialisation, reimbursement) are intended to be partnered.

Customer types and end-markets. NSB has no customers. Its prospective end-market is gastroenterology — specifically adults with Crohn's disease who have failed or are intolerant to approved biologics and small molecules (refractory luminal Crohn's), and patients with perianal fistulising Crohn's disease. Previously studied secondary indications include steroid-refractory graft-versus-host disease (GVHD) and renal transplantation. The legacy EmtinB asset targeted ophthalmology (advanced glaucoma) and neurology (multiple sclerosis, Alzheimer's disease).

Strategy

Stated strategy (paraphrased from FY2026 Annual Report and 2026 ASX releases). Management's strategic themes are: (1) focus resources exclusively on StemSmart™ in immune-mediated inflammatory diseases with large treatment-resistant populations; (2) lead with refractory and fistulising Crohn's disease; (3) secure GMP-compliant, scalable manufacturing through Q-Gen; (4) run a US IND-enabled Phase 2 to generate partner-grade data; (5) monetise non-core EmtinB via out-licensing while preserving upside.

Strategic initiatives — last 24 months.

Medium-term financial targets / guidance. None. Management guides only qualitatively that net losses will continue as clinical development and GMP manufacturing progress (FY2026 Annual Report).

Products & Services

NSB has no marketed products. Its portfolio consists of development-stage assets, catalogued below asset by asset.

StemSmart™ Mesenchymal Stromal/Stem Cell Platform (lead asset)

AttributeDetail
ModalityAllogeneic (donor-derived) bone marrow-sourced MSCs
TechnologyPatented manufacturing process developed at Royal Perth Hospital, designed to enhance therapeutic activity and clinical response and to modulate pathological immune responses (ASX announcement, 13 August 2026)
Mechanism (as described by company)Anti-inflammatory and immunomodulatory activity, dampening inflammation, moderating immune responses and supporting tissue repair (company materials as reported by Biotech Daily, May 2025)
OriginDeveloped 2007; IP registered to Dr Marian Sturm and Isopogen; acquired by NSB 27 June 2025
Accounting carrying valueA$10,270,298 (cost A$11,554,085 less amortisation A$1,283,787), 9-year useful life (FY2026, Note 10)
ManufacturingTransfer from Cell and Tissue Therapies WA (Royal Perth Hospital) to Q-Gen Cell Therapeutics in progress; engineering runs underway ahead of a TGA audit scheduled October 2026; clinical manufacture targeted early CY2027 (FY2026 Annual Report)
Pricing modelNot applicable (pre-commercial)
Royalty burden4% of net sales to EMHS
ProgramIndicationStageKey data / planSource
SAS Category B programFistulising Crohn's disease (patients who exhausted approved therapies)Real-world compassionate use, completed initial cohort5 patients treated; all improved; 4 of 5 achieved protocol-defined "Clinical Response" (over 50% fistula opening closure or over 50% reduction in discharge); no serious adverse eventsFY2026 Annual Report; ASX 26 May 2026
Phase 2 (planned)Refractory (treatment-resistant) Crohn's diseasePre-IND meeting scheduled 31 Aug 2026; CRO appointed 1 Oct 2026; IND submission targeted late CY2026; initiation targeted end-CY2026Australia and US sitesASX 13 Aug 2026; ASX 1 Oct 2026
Phase 2 (planned)Fistulising Crohn's diseasePlanningSecond of two planned Phase 2 programsFY2026 Annual Report
Historic Phase 2 (Isopogen)Refractory Crohn's diseaseCompleted pre-acquisition18 patients; 78% response rate cited by companyFY2026 Annual Report; ASX 16 Apr 2025
Historic Phase 1 (Isopogen)Steroid-refractory GVHD in adultsCompleted pre-acquisitionSupportive safety/activity data citedASX 27 Jun 2025
Historic studiesRenal transplantationCompleted pre-acquisitionCompany described as promisingASX 11 Nov 2025

StemSmart indication-level pipeline.

Target customer. Gastroenterologists and inflammatory bowel disease centres treating refractory and fistulising Crohn's patients; ultimately a licensing partner.

Addressable market (company-cited). Global Crohn's disease market US$13.8 billion by 2026 (ASX announcements, June–July 2025); a figure of US$13 billion is used in the 13 January 2026 release — the discrepancy reflects differing third-party market reports cited.

EmtinB™ (legacy asset — out-licensing)

AttributeDetail
ModalitySynthetic peptide modelled on an active domain of human metallothionein-IIA; binds LDLR-family receptors to activate neuroprotective and neuroregenerative signalling
Indications pursuedAdvanced glaucoma (intravitreal), multiple sclerosis, Alzheimer's disease
Stage reachedIND-enabling; GLP toxicology complete (Jul 2023); FDA pre-IND meeting for glaucoma completed (FY2024); never dosed in humans
LicenceExclusive licence (UTAS); cost A$775,000; fully impaired at 30 June 2026 (impairment A$210,928)
Strategic statusBoard decided in FY2026 not to continue independent development; pursuing out-licensing/partnering

Other Emtin peptides

AssetDescriptionStatus
EmtinAcEmtin family peptide reported to show similar therapeutic potential to EmtinBPreclinical; no recent disclosure
EmtinAnAs abovePreclinical; no recent disclosure
EmtinBnAs abovePreclinical; no recent disclosure

Financial Narrative

All figures A$ millions unless stated. Source: Five-year summary in FY2026 Annual Report Remuneration Report (total income, EBITDA, EBIT, net result, EPS, share price); FY2026 and FY2025 Annual Report financial statements; FY2022–FY2024 balance sheet and cash flow items from S&P Global Market Intelligence data (via StockAnalysis), cross-checked to annual report balances where available. Blank cells = not meaningful or not publicly disclosed.

Income statement

Margins. Gross, operating, EBITDA and net margins are not meaningful because NSB has no operating revenue. Revenue CAGR: not applicable.

Ratios (analyst calculations on year-end balances)

ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a debt-free, pre-revenue company.

Commentary

FY2022 — peak EmtinB spend. The A$10.4M loss in FY2022 reflects the most intensive phase of EmtinB preclinical and CMC work (S&P data attribute A$7.22M to R&D) and A$1.35M of share-based payments. Accounts payable of A$2.17M at year-end show the scale of contracted work outstanding.

FY2023–FY2024 — retrenchment and tax-refund income. Total income of A$5.06M in FY2023 and A$2.39M in FY2024 consisted largely of R&D Tax Incentive refunds relating to the heavy FY2022 spend, which — combined with sharply lower activity — produced a near break-even FY2023 and the company's only profit (A$0.324M) in FY2024. The FY2024 Annual Report states explicitly that the profit mainly reflected the R&D tax incentive. This was not an operational inflection; it was a lagged cash rebate on prior-year spending during a period of strategic drift.

FY2025 — transformational deal year. The loss of A$1.85M was modest in cash terms (operating outflow A$1.13M), but A$0.80M of it was non-cash director/related-party option expense. The balance sheet tripled to A$16.96M as the Isopogen acquisition added A$9.27M of intangibles (funded by 85.7M consideration shares at A$0.08 and 57.1M performance shares initially recognised at 50% probability), while a A$3.5M placement at A$0.035 lifted cash to A$7.27M.

FY2026 — first full year as a cell-therapy company. The loss widened 154% to A$4.69M. Roughly A$1.58M of the increase is non-cash: StemSmart amortisation commenced (A$1.28M) and the EmtinB licence was written off (A$0.21M). Cash costs rose genuinely too: employee costs nearly quadrupled to A$1.01M with the appointment of a CEO, CSO and CMO, and research consultants rose eight-fold to A$1.08M as tech transfer and trial preparation began. Operating cash burn of A$2.78M was partly cushioned by a A$0.40M R&D incentive refund. Quarterly burn has accelerated through the year — A$0.53M in the December 2025 quarter versus A$1.055M in the June 2026 quarter (Appendix 4C reports) — and will rise further when Phase 2 enrolment and GMP batch production begin. A notable accounting feature is the performance-share probability reassessment: when the SAS milestone was met in May 2026, the probability on the Isopogen performance shares was lifted from 50% to 100%, adding A$2.29M to the StemSmart intangible cost base (Note 14), which in turn increases future amortisation.

Balance-sheet quality. Tangible book value is only A$4.54M; 68% of total assets is a single acquired intangible. Cash and term deposits of A$4.63M against a run-rate quarterly burn of about A$1.0–1.1M imply roughly four quarters of funding before trial-related step-ups — the directors nonetheless state funding is sufficient for at least twelve months from 25 August 2026 (FY2026 Annual Report, going concern note).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProductsStatus

Research & development (Australia)

All activities of the group

StemSmart™ MSC platform; EmtinB™ (out-licensing)

Pre-revenue

Results by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

R&D segment total income incl. interest and R&D incentive (AUD Mn)

2.3910.1660.629

R&D segment pre-tax result (AUD Mn)

0.324-1.846-4.693

Share of group total income (%)

100100100

Group Entities

EntityRoleOwnership

NeuroScientific Biopharmaceuticals Limited

ASX-listed parent; holds EmtinB licence

—

Isopogen WA Pty Ltd (converted from Ltd in FY2026)

Holds or has the right to exploit StemSmart™ IP

100%

Isopogen Pty Ltd

Group entity

100%

Isopogen Australia Pty Ltd

Group entity

100%

Isopogen Australia Opco Pty Ltd

Operating entity; counterparty to Q-Gen manufacturing contract

100%

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (AUD Mn)

00000

Total income incl. interest and R&D incentive (AUD Mn)

0.0685.0602.3910.1660.629

EBITDA (AUD Mn)

-10.370-1.0110.416-1.753-3.308

EBIT / operating result (AUD Mn)

-10.435-1.0690.324-1.846-4.692

Pre-tax income (AUD Mn)

-10.435-1.0690.324-1.846-4.693

Net income (AUD Mn)

-10.435-1.0690.324-1.846-4.693

EPS basic (AUD cents)

-7.27-0.740.22-1.26-1.39

EPS diluted (AUD cents)

-7.27-0.740.22-1.26-1.39

Dividends per share (AUD cents)

00000

Weighted avg shares basic (M)

———146.66337.27

Expense line (AUD)

Expense line (AUD)FY2025FY2026

Administration

228,724251,808

Consultants – professional

309,557531,247

Consultants – research

128,7301,083,616

Conferences and travel

098,018

Insurance

129,234131,106

Patent costs

-473144,382

Employee expenses

272,5761,012,534

Management fees

50,00050,000

Share-based payments

798,000421,028

Depreciation

5,59013,249

Amortisation

87,1901,370,975

Impairment (EmtinB licence)

0210,928

Finance costs

2,4633,671

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

7.745.295.4416.9615.18

Cash and equivalents (AUD Mn)

7.224.914.957.272.63

Term deposits (AUD Mn)

00002.00

Cash plus term deposits (AUD Mn)

7.224.914.957.274.63

Short-term debt incl. leases (AUD Mn)

00000.048

Long-term debt incl. leases (AUD Mn)

00000.039

Net cash (AUD Mn)

7.224.914.957.274.54

Total equity (AUD Mn)

5.524.695.3516.8114.81

Goodwill (AUD Mn)

00000

Intangible assets (AUD Mn)

0.320.270.399.5710.27

Working capital (AUD Mn)

5.184.414.967.254.46

Total liabilities (AUD Mn)

2.220.600.090.150.37

Shares outstanding (M)

143.47143.47144.60332.58389.72

NTA per share (AUD cents)

———2.221.26

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-6.94-2.300.04-1.13-2.78

Capex (AUD Mn)

00000

Free cash flow (AUD Mn)

-6.95-2.300.04-1.13-2.78

Equity raised (AUD Mn)

0003.500

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

R&D tax incentive received in operating cash (AUD Mn)

———00.403

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on ending equity (%)

-189.0-22.86.1-11.0-31.7

ROA on ending assets (%)

-134.8-20.26.0-10.9-30.9

Current ratio (x)

3.338.3556.049.614.3

Debt to equity (x)

00000.006

Region Assets & Liabilities

RegionFY2024FY2025FY2026

Australia revenue (AUD Mn)

000

Americas revenue (AUD Mn)

000

EMEA revenue (AUD Mn)

000

APAC ex-Australia revenue (AUD Mn)

000

Australia non-current assets (AUD Mn)

0.399.5710.39

Share Price and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.180.080.040.0870.059

Shares outstanding at 30 June (M)

143.47143.47144.60332.58389.72

Market capitalisation at 30 June (AUD Mn)

25.811.55.828.923.0

Dividends per share (AUD cents)

00000

Valuation Multiples

MultipleNSBComment

Market capitalisation

approx. A$22.6M

389.72M x A$0.058

Enterprise value

approx. A$18.1M

Less net cash A$4.54M (30 Jun 2026)

P/B

approx. 1.5x

Book equity A$14.81M

P/Tangible book

approx. 5.0x

Tangible book A$4.54M

Capital Markets

ItemStatus

Analyst consensus

No broker coverage identified; not publicly available

Dividend policy

No dividends ever paid; none expected

Buyback authorisation

None (FY2026 AR Note 13)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No borrowings; lease liabilities A$48,311 due within 1 year and A$38,728 in 1–2 years

Options on issue (date of FY2026 report)

250,000 at A$0.40 (exp. Jun 2027); 40,000,000 at A$0.07 (exp. Jun 2028); 1,500,000 at A$0.15 and 1,500,000 at A$0.25 (exp. Sep 2028) — 43.25M total

Performance rights

1,500,000 (CEO)

Fully diluted shares

approx. 434.5M

Analyst Conclusions

Management guidance. No financial guidance. Operational targets: TGA audit of Q-Gen in October 2026; IND submission by late CY2026; initiation of Phase 2 trials by end CY2026; clinical manufacturing for trials in early CY2027; continued losses expected (FY2026 Annual Report; ASX 13 Aug 2026; ASX 1 Oct 2026).

Consensus growth expectations. None available (no sell-side coverage).

Bull case

  1. Data that already looks unusually good. Responses in 4 of 5 heavily pre-treated fistulising patients, alongside a 78% response rate in an earlier 18-patient study, suggest StemSmart may outperform first-generation MSC products — if replicated, this is partnerable.

  2. A cleared field in fistulising Crohn's. With Alofisel withdrawn in Europe, a credible bone-marrow MSC with US IND data could become the leading cell-therapy candidate in this niche.

  3. Asymmetric valuation. An enterprise value of roughly A$18M for a Phase 2-ready asset, a management team incentivised toward a US$150M+ deal, and a zero-book EmtinB option offer substantial upside relative to downside if milestones land.

Bear case

  1. Funding gap. A$4.63M cash and a quarterly burn already above A$1M, before two Phase 2 trials and GMP batches, make a dilutive raise at or near depressed prices highly likely in the next 12 months.

  2. Data quality. Small, uncontrolled, single-centre datasets in a field with a history of Phase 3 failures may not survive a randomised design; the market's reaction (share price roughly halved since January 2026 despite good news) suggests scepticism.

  3. Execution and comparability. A manufacturing transfer from a hospital lab to a CMO, a pending TGA audit and FDA expectations on potency assays create meaningful scope for delay, with a 4% royalty and a seemingly short patent life eroding the eventual economics.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Disclosure of FDA pre-IND meeting outcomeOverdue / any timeTrial design clarity and US pathway
TGA audit outcome for Q-GenOct 2026 onwardGates clinical supply
September 2026 quarterly / Appendix 4CLate Oct 2026Burn rate and cash
AGMLikely Nov 2026Placement capacity resolutions, board renewal
IND submission and FDA clearanceLate CY2026 / early CY2027US enrolment
First patient dosed in Phase 2Targeted end CY2026; clinical supply early CY2027Execution credibility
Capital raiseLikely within 12 monthsDilution and price
EmtinB out-licenceUndatedNon-dilutive upside
Escrow releasesOngoingSupply overhang

Concluding analyst verdict

NeuroScientific Biopharmaceuticals is no longer the company its name implies. Since June 2025 it has been a single-asset cell-therapy developer whose fortunes rest on whether StemSmart™, a bone-marrow MSC product refined at Royal Perth Hospital, can reproduce in a controlled, multi-centre Phase 2 what it has shown in small, uncontrolled settings. The early evidence is genuinely encouraging: four of five refractory fistulising Crohn's patients responding without serious adverse events is a striking result in a population that has exhausted approved therapy, and it aligns with the 78% response rate reported in Isopogen's earlier 18-patient study. The strategic logic is also coherent. Takeda's withdrawal of Alofisel in Europe has left a visible gap, the FDA has now approved an allogeneic MSC product, and management has wisely chosen a partner-oriented model with outsourced manufacturing and clinical execution.

The problem is capital, not concept. With A$4.63M in cash and term deposits, a June-quarter burn of A$1.06M and two Phase 2 trials plus GMP manufacturing still to be funded, NSB will almost certainly need to raise equity — likely before the most value-accretive data are available. The share-price trajectory since January 2026 suggests the market is pricing this dilution in. Governance is lean, the asset is encumbered by a 4% royalty, and the amortisation schedule hints at a relatively short patent runway.

On balance, NSB is a high-risk, binary, speculative development-stage holding. The near-term value drivers are procedural but important: disclosure of FDA pre-IND feedback, a clean TGA audit of Q-Gen, IND clearance and first-patient dosing. Successful delivery of all four within roughly six months, followed by a raise on acceptable terms, would materially de-risk the story; slippage on any of them, combined with a weak market for micro-cap biotech, would likely force financing at punitive levels. Until the controlled data arrive, conviction should remain low and position sizing small.


Source list (primary): NSB FY2026 Annual Report and Appendix 4E (25 Aug 2026); FY2025 Annual Report (28 Aug 2025); FY2024 Annual Report (29 Aug 2024); FY2023 Annual Report (25 Aug 2023); FY2022 Annual Report (30 Aug 2022); FY2020 Annual Report (28 Aug 2020); ASX announcements 27 Jun 2025, 23 Jul 2025, 31 Jul 2025, 30 Oct 2025, 30 Jan 2026, 28 Jul 2026, 13 Aug 2026, 1 Oct 2026. Secondary: StockAnalysis (S&P Global Market Intelligence data); Morningstar Australia; Market Index; InvestSMART announcement summaries; StockLight; Quartr event summaries; Stockhead (Dr Boreham's Crucible, May 2025; 2019 special report); Biotech Daily (3 Jul 2019; 16 May 2025); Biotech Dispatch; Business News WA; Kalkine Media; Medianet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationShares heldOptions held

Robert McKenzie

Non-Executive Chairman

27 Jun 2025

Lawyer, over 45 years in corporate/commercial transactions, restructuring and disputes; former partner Clayton Utz (head of reconstruction and insolvency) and Jackson McDonald; Chair of the Perron Institute; director and risk committee chair at Keystart; former Takeovers Panel member

LL.B, B.Juris, FAICD, RITF

9,635,7925,000,000

Paul Fry

Non-Executive Director; also part-time Commercial Officer

27 Jun 2025

Former partner of EY and PwC in Australia and Canada; capital markets, governance and transactions

BBus

22,471,6025,000,000

Clarke Barlow

Non-Executive Director

5 Dec 2023

Financial adviser and capital markets specialist, over 20 years in Australia and UK; former NED Tryptamine Therapeutics (ASX:TYP)

BCom, MAICD

Nil

1,000,000

Dr Anton Uvarov

Non-Executive Director

6 Sep 2017

Healthcare equity analyst; formerly Citigroup Global Markets NY biotech team; Executive Director BlinkLab (ASX:BB1); NED Patrys (ASX:PAB)

PhD, MBA

5,000,0001,000,000

Executive Leadership Team

NameTitleAppointedBackgroundTerms

Nathan Smith

Chief Executive Officer

28 Jul 2025

Cell and gene therapy executive; senior roles including Cell Therapies Pty Ltd and GlaxoSmithKline (USA); GMP manufacturing and scale-up expertise

A$250,000 + super; 3M options; 1.5M performance rights

Dr Marian Sturm

Chief Scientific Officer

23 Jul 2025

Inventor of StemSmart; long-time Royal Perth Hospital/EMHS cell therapy scientist; inaugural member of TGA advisory committee on biologics; largest individual shareholder

A$175,000 pro rata at 0.8 FTE

Dr Catherine Cole

Chief Medical Officer

24 Jul 2025

Former Head of Haematology and Oncology at Princess Margaret Hospital and Perth Children's Hospital; Director of Haematopoietic Stem Cell Transplantation

A$500,000 pro rata at 0.2 FTE

Chris Achurch

Company Secretary

—

Company secretary to multiple ASX companies

—

“—” = not publicly disclosed.

Directors' Remuneration

NameSalary/feesSuperannuationBonus (STI)Share-basedTotal

Robert McKenzie

80,0009,6000089,600

Paul Fry

154,74718,57000173,317

Clarke Barlow

55,0006,6000061,600

Anton Uvarov

50,00000050,000

Nathan Smith

238,91327,9640421,028687,905

Marian Sturm

144,51516,95000161,465

Catherine Cole

102,61411,50000114,114

Total KMP

825,78991,1840421,0281,338,001

Board & Management Changes

DateChangeContext

FY2024

Dougal Thring (COO) resigned; Dr Tony Keating appointed Executive Director

EmtinB FDA engagement phase

27 Jun 2025

Chris Ntoumenopoulos (Chair) and Tony Keating resigned; McKenzie and Fry appointed

Isopogen completion

21 Jun 2026

5M director options lapsed (A$1.27M reserve transferred)

Legacy options expiry

Jul 2025

CEO, CSO, CMO appointed

Build-out of cell therapy team

Competitive Landscape

Key Competitors

CompetitorSegmentRelevant product / approachRelative positioning vs NSB

Takeda

Fistulising Crohn's cell therapy; biologics

Alofisel (darvadstrocel, adipose MSC) — withdrawn in EU after confirmatory trial failure; Entyvio (vedolizumab)

Validated the indication then retreated, leaving a gap; also dominant biologic incumbent

Mesoblast (ASX: MSB)

Allogeneic MSC therapy

Ryoncil (remestemcel-L) approved by FDA for paediatric steroid-refractory acute GVHD

Closest listed Australian MSC peer; far larger, with an approved product and manufacturing scale

Cynata Therapeutics (ASX: CYP)

iPSC-derived MSCs

Cymerus platform; GVHD and other inflammatory indications

Alternative MSC sourcing technology; similar micro/small-cap ASX peer

AbbVie

Crohn's biologics/small molecules

Humira, Skyrizi, Rinvoq

Standard-of-care incumbents that define the "refractory" population NSB targets

Johnson & Johnson

Crohn's biologics

Stelara, Tremfya

Incumbent; potential partner

Eli Lilly

Crohn's biologics

Omvoh (mirikizumab)

Incumbent; potential partner

Pfizer

IBD small molecules

Velsipity (UC), pipeline

Adjacent

Pluri (formerly Pluristem)

Placental cell therapy

Inflammatory/regenerative programs

Cell-therapy peer

Longeveron

Allogeneic MSC

Laromestrocel (cardiac, ageing indications)

MSC peer, different indications

Academic/hospital MSC programs (e.g., Leiden bone-marrow MSC for perianal fistula)

Fistulising Crohn's

Local injection MSC studies

Scientific competition for the same niche

Peer Comparison FY2026

MetricNSB (FY2026)MesoblastCynataTakeda

Revenue

A$0

———

Approved MSC product

—

Ryoncil (US)

—

Alofisel (withdrawn EU)

Stage in Crohn's

Phase 2 planned

Not a stated focus

Not a stated focus

Exited cell therapy indication in EU

Recent Developments

--

Company Snapshot

1

Employees

2002

Founded

Perth, Australia

Headquarters

SWOT Analysis

Strengths

  • Human efficacy signals already exist: 4 of 5 SAS fistulising Crohn's patients achieved protocol-defined clinical response with no serious adverse events (ASX 26 May 2026; FY2026 Annual Report).
  • Prior controlled-setting data: historic Phase 2 in 18 refractory Crohn's patients with a 78% response rate cited by the company (FY2026 Annual Report).
  • Debt-free balance sheet: total liabilities only A$0.37M at 30 June 2026, consisting mainly of payables and a small lease (FY2026 Annual Report).
  • Inventor alignment: Dr Sturm, StemSmart's inventor and former TGA biologics advisory committee member, is CSO and holds about 10.6% of shares (FY2026 Annual Report).
  • Experienced cell-therapy operator as CEO: Nathan Smith's GMP and scale-up background (ex-Cell Therapies Pty Ltd, GSK USA) matches the gating manufacturing risk (ASX Oct 2025 quarterly).
  • Established manufacturing partner: Q-Gen is TGA-licensed with 13 cell-therapy cleanrooms and 25+ years' experience (ASX 31 Jul 2025).

Weaknesses

  • Thin cash runway: A$4.63M cash and deposits against a June 2026 quarterly operating outflow of A$1.055M (Appendix 4C, 28 Jul 2026).
  • Single-asset concentration: StemSmart represents A$10.27M of A$15.18M total assets; EmtinB written to nil (FY2026 Note 10).
  • Small, non-randomised datasets: SAS cohort of 5 patients; historic trial of 18 — insufficient for regulatory efficacy claims.
  • Thin governance structures: no audit, risk or remuneration committees; one director also an employee/consultant (FY2026 Annual Report).
  • Royalty encumbrance: 4% of net sales to EMHS plus EMHS right to cells at cost for public patients (FY2026 Note 20).
  • Track record of non-delivery on prior asset: EmtinB never reached human dosing across seven years of listed development despite A$20M+ of cumulative losses (accumulated losses A$26.7M at 30 June 2026).

Opportunities

  • Competitive vacuum in fistulising Crohn's following withdrawal of Takeda's Alofisel in Europe.
  • US IND pathway: IND submission targeted late CY2026 enables US-relevant data that partners value (ASX 13 Aug 2026).
  • Partnering upside: management explicitly targets a deal of at least US$150M headline value (CEO performance-rights hurdle, FY2026 Annual Report).
  • Indication expansion: prior GVHD Phase 1 and renal transplant studies (ASX 27 Jun 2025; 11 Nov 2025).
  • Regulatory precedent: FDA approval of an allogeneic MSC product (Mesoblast's Ryoncil) improves sector sentiment.
  • EmtinB monetisation: any out-licence would be pure upside, as the asset carries zero book value.

Threats

  • Dilution: share price A$0.058 sits below the A$0.07 strike of 40M options, so options are unlikely to fund the company; a further capital raise is probable within 12 months.
  • Manufacturing comparability risk: process transfer from Royal Perth Hospital to Q-Gen must reproduce potency; TGA audit scheduled October 2026 (FY2026 Annual Report).
  • MSC sector clinical failure history, including Alofisel's confirmatory trial failure.
  • Biologic innovation shrinking the refractory population.
  • Escrow release / overhang from vendor shares (escrow update 19 June 2026) and converted performance shares.
  • Share price weakness: price fell from about A$0.115 at the January 2026 result to A$0.058 by October 2026 despite positive news, signalling investor concern about funding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Agreement to acquire Isopogen WA / StemSmartStrategic pivot
23 May 2025A$3.5M placement announced at A$0.035Funding for pivot
26 May 2025Appendix 3B for placementCapital structure
27 Jun 2025Acquisition complete; cash approx. A$7.5M; new directorsPivot executed
27 Jun 202540M options at A$0.07 issued (directors 14M, lead manager 26M)Dilution overhang
23 Jul 2025June 2025 quarterly; cash A$7.3MBaseline
23–28 Jul 2025CSO, CMO and CEO appointedTeam built
31 Jul 2025Q-Gen manufacturing partnershipSupply chain
28 Aug 2025FY2025 Annual Report; loss A$1.85MResults
15 Sep 2025CEO options and performance rights issuedIncentives
30 Oct 2025September quarterly; previous studies support renal transplantationPipeline breadth
11 Nov 2025Fourth SAS patient commenced treatmentClinical progress
Dec 2025 qtrClinical & Scientific Advisory Board formedGovernance of science
9 Jan 2026Trading halt pending SAS results—
13 Jan 20263 of 4 SAS patients achieve clinical response; Phase 2 planned H2 2026Major value inflection; shares +43.5%
30 Jan 2026December quarterly; cash approx. A$6.4M; quarterly operating outflow A$532kBurn baseline
16 Feb 2026Company presentationInvestor outreach
25 Feb 2026Half-year report; H1 FY2026 loss A$1.70M vs A$0.37M priorRising costs
17 Mar 2026Media coverage of stem-cell supply scale-up for trialsManufacturing
Mar–Apr 2026Two-year office lease signed, commencing 1 April 2026Footprint
30 Apr 2026March quarterly; cash A$5.68M; tech transfer to Q-Gen commencedProgress
25 May 2026Trading halt—
26 May 20265 SAS patients all improved; 4 of 5 clinical responders; milestone metPerformance shares triggered
1 Jun 202657.1M performance shares converted; Section 708A notice17% increase in shares on issue
9 Jun 2026Change in substantial holdingRegister change
11 Jun / 16 Jun 2026Investor webinar and CEO/CSO status updateEngagement
19 Jun 2026Escrowed securities updatePotential supply release
21 Jun – 1 Jul 20265M director options lapsed; cessation noticeHousekeeping
21 Jul 2026StemSmart presentation at ISCT ANZ 2026Scientific profile
28 Jul 2026June quarterly; cash A$4.6M; quarterly operating outflow A$1.055M; two Phase 2 trials plannedBurn doubling
13 Aug 2026FDA pre-IND meeting scheduled for 31 Aug 2026; IND targeted late CY2026Regulatory milestone
25 Aug 2026FY2026 Annual Report; loss A$4.69M; EmtinB to be out-licensed and fully impairedPortfolio rationalisation
31 Aug 2026Pre-IND meeting date (outcome not located in sources reviewed)Monitorable
1 Oct 2026Southern Star Research appointed CRO; trial initiation targeted end CY2026Execution step
Oct 2026 (scheduled)TGA audit of Q-Gen to extend licence to StemSmart clinical manufactureGating item

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (%): Share of group total income held from 100% in FY2024 to 100% in FY2026.
NeuroScientific Biopharmaceuticals Limited — Revenue by Segment (%)
Series (%)FY2024FY2025FY2026
Share of group total income100100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.